135 related articles for article (PubMed ID: 31280877)
1. Progressive cardiovascular disease in a patient under treatment with nilotinib.
Roa-Chamorro R; Torres-Quintero L; García de Los Ríos C; Puerta-Puerta JM; González-Bustos P; Mediavilla-García JD
Clin Investig Arterioscler; 2020; 32(2):66-69. PubMed ID: 31280877
[TBL] [Abstract][Full Text] [Related]
2. Severe peripheral arterial disease during nilotinib therapy.
Le Coutre P; Rea D; Abruzzese E; Dombret H; Trawinska MM; Herndlhofer S; Dörken B; Valent P
J Natl Cancer Inst; 2011 Sep; 103(17):1347-8. PubMed ID: 21813414
[No Abstract] [Full Text] [Related]
3. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up.
Aghel N; Lipton JH; Atenafu EG; Kim DDH; Delgado DH
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):870-878.e1. PubMed ID: 28803825
[TBL] [Abstract][Full Text] [Related]
5. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study.
Levato L; Cantaffa R; Kropp MG; Magro D; Piro E; Molica S
Eur J Haematol; 2013 Jun; 90(6):531-2. PubMed ID: 23506097
[No Abstract] [Full Text] [Related]
6. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
Mirault T; Rea D; Azarine A; Messas E
Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
[TBL] [Abstract][Full Text] [Related]
7. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
[TBL] [Abstract][Full Text] [Related]
8. Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion.
Maurizot A; Beressi JP; Manéglier B; de la Marre NH; Spentchian M; Soury P; Solvet-Sebire P; Collet-Gaudillat C; Baud JM; Livarek B; Guilhot F; Rousselot P
Blood Cancer J; 2014 Sep; 4(9):e247. PubMed ID: 25238138
[No Abstract] [Full Text] [Related]
9. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.
Tefferi A; Letendre L
Am J Hematol; 2011 Jul; 86(7):610-1. PubMed ID: 21630307
[No Abstract] [Full Text] [Related]
10. Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.
Sarlon-Bartoli G; Michel Q; Sarlon E; Carcopino-Tusoli M; Suchon P; Soler R; Bartoli MA; Brunet D; Morange P; Charbonnier A
J Med Vasc; 2021 Apr; 46(2):66-71. PubMed ID: 33752848
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
Tefferi A
Leukemia; 2013 Sep; 27(9):1939-40. PubMed ID: 23604230
[No Abstract] [Full Text] [Related]
12. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD
Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449
[TBL] [Abstract][Full Text] [Related]
13. T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.
Hanley B; Nesr G; Yebra-Fernandez E; Brown L; Rabitsch A; Killeen N; Claudiani S; Milojkovic D; Kanfer E; Apperley J; Naresh KN
J Clin Pathol; 2019 Jul; 72(7):511-512. PubMed ID: 31004076
[No Abstract] [Full Text] [Related]
14. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
15. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Cortes J; Mauro M; Steegmann JL; Saglio G; Malhotra R; Ukropec JA; Wallis NT
Am J Hematol; 2015 Apr; 90(4):E66-72. PubMed ID: 25580915
[TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting].
García-Gutiérrez V; Jiménez-Velasco A; Gómez-Casares MT; Sánchez-Guijo F; López-Sendón JL; Steegmann Olmedillas JL
Med Clin (Barc); 2016 Jun; 146(12):561.e1-8. PubMed ID: 27107729
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics of vascular adverse events and significance of peripheral artery disease as a risk factor in chronic myeloid leukemia patients treated with nilotinib].
Sumi M; Sato K; Uematsu N; Kawaguchi H; Shishido T; Kaiume H; Takeda W; Kirihara T; Ueki T; Hiroshima Y; Ueno M; Ichikawa N; Urasawa N; Kobayashi H
Rinsho Ketsueki; 2018; 59(2):137-144. PubMed ID: 29515064
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke.
Kakadia B; Thakkar R; Sanborn E; Suero-Abreu GA; Jovin TG; Then R
J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105883. PubMed ID: 34090174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
